In an exclusive interview with PropThink.com, Thrombogenics (EBR:THR)(OTC:TBGNF) CEO Patrik De Haes discusses the company’s pending FDA and EMA approvals of ocriplasmin, a treatment for symptomatic vitreomacular adhesion. Current procedures in the 500,000 patient market require a week-long recovery period in which the patient remains immobilized face-down. Ocriplasmin, says De Haes, is an outpatient treatment that requires one injection and no recovery time. Not only is it faster, but De Haes says the injection may cost as little as €2000, a fraction of current $10,000 options in the U.S. He expects a late summer advisory meeting and commercialization in the U.S. and Europe – with a helping hand from partner Alcon, a division of Novartis (NYSE:NVS) – in Q1 of 2013.
De Haes also discusses results from studies of Thrombogenics’ pipeline drug TB-402, a post-surgery anticoagulant that has shown increased efficacy and similar safety to Xarelto by Bayer (OTC:BAYRY), and Lovenox by Sanofi (NYSE:SNY).